Animal Health CRO & CDMO Update – Market Trends & 2022 Outlook – 28 September 2021

  • Private Equity
  • Healthcare
  • Global


Former Senior Scientific Executive at Parnell Veterinary Pharmaceuticals Holdings Ltd


  • Trends and developments relating to animal health CROs (contract research organisations) and CDMOs (contract development and manufacturing organisations), including regulatory shifts and complex therapeutics
  • Convergence between animal health and human health outsourcing partners and margin profile comparison
  • Consolidation and M&A, including in veterinary clinics and pharmaceuticals
  • Developments in production animals vs companion animals, especially post-coronavirus
  • Outlook for Q4 2021 and beyond – potential repurposing of human health drugs into animal health


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited